Amalgamated Bank Grows Stock Holdings in Exelixis, Inc. $EXEL

Amalgamated Bank raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 136,252 shares of the biotechnology company’s stock after acquiring an additional 2,331 shares during the quarter. Amalgamated Bank’s holdings in Exelixis were worth $6,005,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of EXEL. Belpointe Asset Management LLC purchased a new position in shares of Exelixis during the first quarter valued at about $572,000. GAMMA Investing LLC increased its position in shares of Exelixis by 32.2% during the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 1,328 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Exelixis by 23.9% during the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock valued at $9,159,000 after buying an additional 47,845 shares during the period. Fortis Capital Advisors LLC purchased a new position in shares of Exelixis during the first quarter valued at about $572,000. Finally, Intech Investment Management LLC increased its position in shares of Exelixis by 46.4% during the first quarter. Intech Investment Management LLC now owns 392,022 shares of the biotechnology company’s stock valued at $14,473,000 after buying an additional 124,297 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on EXEL. Leerink Partnrs upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 21st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $45.00 price target on shares of Exelixis in a research report on Tuesday, October 21st. Morgan Stanley cut their price objective on shares of Exelixis from $50.00 to $44.00 and set an “overweight” rating on the stock in a report on Tuesday, October 21st. Wall Street Zen upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Truist Financial cut their price objective on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and an average target price of $44.53.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $38.67 on Friday. The firm’s 50 day moving average price is $38.81 and its 200-day moving average price is $40.23. The company has a market cap of $10.41 billion, a PE ratio of 18.59, a P/E/G ratio of 0.79 and a beta of 0.38. Exelixis, Inc. has a 52-week low of $31.90 and a 52-week high of $49.62.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.